Globus Medical climbs on better-than-expected Q4, FY outlook

Medical device maker Globus Medical's GMED.N shares rise 8.4% to $98.17 premarket, set to open at a record high if current gains hold

Co expects Q4 sales of $823.2 mln vs analysts' average estimate of $776.8 mln - data compiled by LSEG

Attributes stronger performance to spinal surgery products and enabling technologies

GMED expects FY26 adj. EPS between $4.30 and $4.40 vs estimate of $3.82

Three brokerages raise PT

We think GMED is well-positioned to grow above market - Jefferies

Nine of 15 brokerages rate the stock "buy" or higher, six "hold"; their median PT is $105 - data compiled by LSEG

GMED shares gained 5.6% last year